DCRI Awarded up to $102.5M for Work on Antibacterial Resistance

December 17, 2019

Applied Clinical Trials

The Antibacterial Resistance Leadership Group (ARLG), a unique research network for which the Duke Clinical Research Institute (DCRI) acts as a coordinating center, received a federal award worth up to $102.5 million over seven years that will continue the ARLG. The Antibacterial Resistance Leadership Group conducts clinical research to better understand how to diagnose, treat, and prevent antibacterial resistant infections.

To learn more, click here.